Evidence map›Paper›PMID 34362925›Full record

ArticleNature communications2021

An omics-based framework for assessing the health risk of antimicrobial resistance genes.

An-Ni Zhang, Jeffry M Gaston, Chengzhen L Dai, Shijie Zhao, Mathilde Poyet, Mathieu Groussin, Xiaole Yin, Li-Guan Li, Mark C M van Loosdrecht, Edward Topp and 6 more

Abstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 226 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
226citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

226 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Soil management practices shape the abundance, diversity, and spread of antimicrobial resistance.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

166 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

An-Ni ZhangEnvironmental Microbiome Engineering and Biotechnology Laboratory, Department of Civil Engineering, The University of Hong Kong, Hong Kong SAR, China.
Jeffry M GastonGoogle, Cambridge, USA.ORCID 0000-0001-7431-254X
Chengzhen L DaiDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, USA.ORCID 0000-0002-3073-211X
Shijie ZhaoDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, USA.
Mathilde PoyetDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, USA.
Mathieu GroussinDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, USA.ORCID 0000-0002-0942-7217
Xiaole YinEnvironmental Microbiome Engineering and Biotechnology Laboratory, Department of Civil Engineering, The University of Hong Kong, Hong Kong SAR, China.
Li-Guan LiEnvironmental Microbiome Engineering and Biotechnology Laboratory, Department of Civil Engineering, The University of Hong Kong, Hong Kong SAR, China.
Mark C M van LoosdrechtDepartment of Biotechnology, Delft University of Technology, Delft, The Netherlands.ORCID 0000-0003-0658-4775
Edward ToppLondon Research and Development Centre (LRDC), Agriculture and Agri-Food Canada, London, ON, Canada.
Michael R GillingsDepartment of Biological Sciences, Macquarie University, Sydney, NSW, Australia.ORCID 0000-0002-4043-4351
William P HanageCenter for Communicable Disease Dynamics, Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, USA.
James M TiedjeDepartment of Plant, Soil and Microbial Sciences and of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI, USA.
Katya MonizDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, USA.
Eric J AlmDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, USA.
Tong ZhangEnvironmental Microbiome Engineering and Biotechnology Laboratory, Department of Civil Engineering, The University of Hong Kong, Hong Kong SAR, China. zhangt@hku.hk.ORCID 0000-0003-1148-4322

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibiotic resistance genes (ARGs) are widespread among bacteria. However, not all ARGs pose serious threats to public health, highlighting the importance of identifying those that are high-risk. Here, we developed an 'omics-based' framework to evaluate ARG risk considering human-associated-enrichment, gene mobility, and host pathogenicity. Our framework classifies human-associated, mobile ARGs (3.6% of all ARGs) as the highest risk, which we further differentiate as 'current threats' (Rank I; 3%) - already present among pathogens - and 'future threats' (Rank II; 0.6%) - novel resistance emerging from non-pathogens. Our framework identified 73 'current threat' ARG families. Of these, 35 were among the 37 high-risk ARGs proposed by the World Health Organization and other literature; the remaining 38 were significantly enriched in hospital plasmids. By evaluating all pathogen genomes released since framework construction, we confirmed that ARGs that recently transferred into pathogens were significantly enriched in Rank II ('future threats'). Lastly, we applied the framework to gut microbiome genomes from fecal microbiota transplantation donors. We found that although ARGs were widespread (73% of genomes), only 8.9% of genomes contained high-risk ARGs. Our framework provides an easy-to-implement approach to identify current and future antimicrobial resistance threats, with potential clinical applications including reducing risk of microbiome-based interventions.

Indexed as

Anti-Bacterial AgentsBacteriaDatabases, FactualDrug Resistance, BacterialGastrointestinal MicrobiomeGenes, BacterialGenomeHumansMetagenomePlasmidsAnti-Bacterial Agents

Identifiers

PMID34362925
PMCPMC8346589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.